HRP20250632T1 - Nlrp3 inhibitori - Google Patents

Nlrp3 inhibitori

Info

Publication number
HRP20250632T1
HRP20250632T1 HRP20250632TT HRP20250632T HRP20250632T1 HR P20250632 T1 HRP20250632 T1 HR P20250632T1 HR P20250632T T HRP20250632T T HR P20250632TT HR P20250632 T HRP20250632 T HR P20250632T HR P20250632 T1 HRP20250632 T1 HR P20250632T1
Authority
HR
Croatia
Prior art keywords
methyl
hydroxy
triazin
phenyl
amino
Prior art date
Application number
HRP20250632TT
Other languages
English (en)
Croatian (hr)
Inventor
Lea Aurelie BOUCHE
Wolfgang Guba
Georg Jaeschke
Stefanie Katharina MESCH
Andreas Michael TOSSTORFF
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20250632T1 publication Critical patent/HRP20250632T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HRP20250632TT 2021-05-12 2022-05-10 Nlrp3 inhibitori HRP20250632T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21173452 2021-05-12
EP21209447 2021-11-22
EP21215859 2021-12-20
PCT/EP2022/062525 WO2022238347A1 (en) 2021-05-12 2022-05-10 Nlrp3 inhibitors
EP22728228.2A EP4337652B1 (en) 2021-05-12 2022-05-10 Nlrp3 inhibitors

Publications (1)

Publication Number Publication Date
HRP20250632T1 true HRP20250632T1 (hr) 2025-07-18

Family

ID=81941106

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20250632TT HRP20250632T1 (hr) 2021-05-12 2022-05-10 Nlrp3 inhibitori

Country Status (25)

Country Link
US (1) US20240208928A1 (https=)
EP (2) EP4337652B1 (https=)
JP (1) JP2024517917A (https=)
KR (1) KR20240007152A (https=)
AR (1) AR125818A1 (https=)
AU (1) AU2022275300A1 (https=)
BR (1) BR112023023527A2 (https=)
CA (1) CA3214626A1 (https=)
CL (1) CL2023003312A1 (https=)
CO (1) CO2023016204A2 (https=)
CR (1) CR20230529A (https=)
DK (1) DK4337652T3 (https=)
ES (1) ES3031704T3 (https=)
FI (1) FI4337652T3 (https=)
HR (1) HRP20250632T1 (https=)
HU (1) HUE071498T2 (https=)
IL (1) IL307188A (https=)
LT (1) LT4337652T (https=)
MA (1) MA64323B1 (https=)
MX (1) MX2023012907A (https=)
PE (1) PE20240126A1 (https=)
PL (1) PL4337652T3 (https=)
RS (1) RS66893B1 (https=)
SI (1) SI4337652T1 (https=)
WO (1) WO2022238347A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
IL314025A (en) * 2022-01-07 2024-08-01 Transthera Sciences Nanjing Inc Nlrp3 inflammasome inhibitor and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
AU2023371859A1 (en) * 2022-11-04 2025-06-12 Transthera Sciences (Nanjing) , Inc. Nlrp3 inflammasome inhibitor and use thereof
PE20251845A1 (es) * 2022-12-07 2025-07-17 Hoffmann La Roche Compuestos novedosos como moduladores de la inhibicion de nlrp3
WO2024158941A2 (en) * 2023-01-27 2024-08-02 Mwyngil Therapeutics, Inc. Inhibitors of nlrp3
JP2026511027A (ja) * 2023-03-20 2026-04-10 インシリコ メディスン アイピー リミティド Nlrp3インフラマソーム阻害剤及びその使用
WO2024193699A1 (zh) 2023-03-23 2024-09-26 成都赜灵生物医药科技有限公司 三嗪类化合物及其用途
KR20260027946A (ko) 2023-06-02 2026-03-03 머크 샤프 앤드 돔 엘엘씨 Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클
IL324489A (en) 2023-06-29 2026-01-01 Hoffmann La Roche Triazine derivatives as NLRP3 inhibitors
CN121586712A (zh) 2023-07-28 2026-02-27 豪夫迈·罗氏有限公司 新颖化合物
WO2025059069A1 (en) * 2023-09-12 2025-03-20 Zomagen Biosciences Ltd Nlrp3 modulators
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653316B1 (en) * 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3

Also Published As

Publication number Publication date
MX2023012907A (es) 2023-11-08
PL4337652T3 (pl) 2025-07-14
TW202311245A (zh) 2023-03-16
SI4337652T1 (sl) 2025-07-31
RS66893B1 (sr) 2025-07-31
EP4337652B1 (en) 2025-04-09
LT4337652T (lt) 2025-06-25
EP4609865A3 (en) 2025-10-29
KR20240007152A (ko) 2024-01-16
JP2024517917A (ja) 2024-04-23
DK4337652T3 (da) 2025-06-10
AR125818A1 (es) 2023-08-16
BR112023023527A2 (pt) 2024-01-30
CA3214626A1 (en) 2022-11-17
AU2022275300A1 (en) 2023-09-21
MA64323B1 (fr) 2025-06-30
ES3031704T3 (en) 2025-07-10
EP4609865A2 (en) 2025-09-03
PE20240126A1 (es) 2024-01-22
EP4337652A1 (en) 2024-03-20
US20240208928A1 (en) 2024-06-27
FI4337652T3 (fi) 2025-06-20
HUE071498T2 (hu) 2025-09-28
WO2022238347A1 (en) 2022-11-17
CR20230529A (es) 2023-12-04
IL307188A (en) 2023-11-01
CL2023003312A1 (es) 2024-06-21
CO2023016204A2 (es) 2023-12-11

Similar Documents

Publication Publication Date Title
HRP20250632T1 (hr) Nlrp3 inhibitori
JP2024517917A5 (https=)
US10660877B2 (en) Pyridyl substituted indole compounds
RU2016124176A (ru) Композиции тетрагидрохинолинов в качестве ингибиторов бромодомена вет
US20190345138A1 (en) Heterocyclic amides as kinase inhibitors
JP2013545744A5 (https=)
ES2523892T3 (es) Derivados triazol y utilización de los mismos para trastornos neurológicos
US9604963B2 (en) Amino-quinolines as kinase inhibitors
JP2012503018A5 (https=)
HRP20251479T1 (hr) Pesticidno aktivni kondenzirani biciklički heteroaromatski spojevi
JP2019077725A5 (https=)
JP2020530446A5 (https=)
JP2005533803A5 (https=)
JP2023506642A5 (https=)
US20130053375A1 (en) Amino-quinolines as kinase inhibitors
RU2016124178A (ru) Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
HRP20170622T1 (hr) Derivati piridinila i kondenziranog piridinil triazolona
JP2007510689A5 (https=)
JP2019504821A5 (https=)
KR20170042595A (ko) 의약으로서의 rip1 키나제 억제제로서의 헤테로시클릭 아미드
HRP20120457T1 (hr) 4-(4-cijano-2-tioaril)dihidropirimidinoni i njihova uporaba
IL295076B1 (en) Piperidinone derivatives as MDM2 inhibitors for cancer treatment
JP2019505595A5 (https=)
JP2007538011A5 (https=)
JP2020512401A5 (https=)